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Prostate carcinoma is the second leading cause of death from
cancer among men (Catalona, 1994). Prostate cancer is an
androgen-dependent tumour, therefore hormonal therapy is often
used as a primary treatment option for men with symptomatic,
advanced disease. However, 20% of patients are refractory to
treatment (Sinha et al, 1977). Furthermore, virtually all patients
who exhibit an initial therapeutic response will relapse within 3
years with androgen-independent carcinoma that is rapidly fatal
(Sinha et al, 1977; Catalona, 1994). 
Recently, docetaxel has been shown to have marked activity
against prostate cancer cells both in vitro and in vivo. Docetaxel
has been shown to induce programmed cell death in DU145,
LNCaP and PC-3 prostate cancer cells (Haldar et al, 1995, 1996,
1997, 1998). Treatment of prostate cancer cells with docetaxel
induces phosphorylation of Bcl-2 and abrogates the normal anti-
apoptotic function of Bcl-2 (Haldar et al, 1995,1996,1997,1998). 
Petrylak et al have recently shown that the combination of
docetaxel and estramustine is active and well tolerated in patients
with androgen-independent prostate cancer (Petrylak et al, 1999).
The PSA response rate in this phase I trial was 63%. Similarly, a
phase II study of docetaxel, estramustine and low-dose hydrocorti-
sone in men with hormone-refractory prostate cancer conducted
by the Cancer and Leukemia Group B showed a response rate of
69% (Savarese et al, 1999). Monotherapy with docetaxel has also
been shown to be active in patients with androgen-independent
prostate cancer with an objective response rate of 46% (Picus and
Schultz, 1999). 
Retinoids include natural as well as synthetic derivatives of
vitamin A and have been shown to modulate cellular growth and
differentiation of normal and neoplastic epithelial cells by inter-
acting with nuclear receptors that function as retinoid-dependent
transcriptional factors, including the RAR and RXR receptors
(Amos and Lotan, 1990; Mangelsdorf et al, 1994). All-trans
retinoic acid (ATRA) induces growth arrest and differentiation of
diverse tumour cell lines in vitro (Caliaro et al, 1994; Lotan,
1994). Recent studies have shown that ATRA enhances the cyto-
toxicity of chemotherapeutic agents. For instance, ATRA has been
shown to increase the in vitro sensitivity to cisplatin in squamous
head and neck cancer and in ovarian cancer cells (Sacks et al,
1995; Aebi et al, 1997; Caliaro et al, 1997). Formelli et al have
demonstrated in an in vivo model that the synthetic retinoid fenre-
tinide enhanced activity of cisplatin and increased survival of nude
mice bearing ovarian carcinoma xenografts (Formelli and Cleris,
1993). Encouraging clinical results have also been reported for
using retinoids and cytotoxic agents in combination (Seiter et al,
2000). 
In the present study, we investigated the effects of ATRA on
docetaxel-induced cell death and cell cycle arrest in human
prostate cancer cell lines. In addition, we investigated the sig-
nalling pathways which are activated in response to treatment with
ATRA and docetaxel and which regulate apoptotic cell death and
progression through the cell cycle. 
MATERIALS AND METHODS 
Cell culture 
The human hormone-independent DU145 and hormone-dependent
LNCaP prostate cancer cell lines were obtained from American
Type Culture Collection (Rockville, MD, ATCC #HTB-81 and
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DU145 cells and LNCaP cells were cultured in Eagle’s MEM
(Irvine Scientific, Irvine, CA) and RPMI 1640 (Irvine Scientific),
respectively. Medium was supplemented with 100 mM L-gluta-
mine and 10% heat-inactivated fetal bovine serum. 
Reagents 
ATRA was purchased from Sigma Chemical Co (St Louis, MO)
and was dissolved in DMSO as 50mM stock solution. Docetaxel
was obtained from Aventis Pharmaceuticals (Collegeville, PA),
and was prepared as a 50 mM stock solution in polysorbate 80. 
Treatment schedule 
In order to determine the effects of ATRA and docetaxel on
growth inhibition, apoptosis, cell cycle phase distribution, and
protein expression, DU145 and/or LNCaP cells were exposed to
docetaxel for 1 h and to ATRA continuously starting 72 h prior to
docetaxel exposure. The dose of ATRA was fixed at 5 mM. We
have previously shown that in head and neck cells, this schedule
resulted in maximum enhancement of drug sensitivity (Aebi et al,
1997). 
Growth inhibition assays 
Sulforhodamine B growth rate assays were performed according
to the protocol described by Monks et al (1991). Control and
ATRA treated cells were seeded into 96-well plates at a density of
6000 cells well–1 in 100 ml medium. After 24 h, cells were exposed
to docetaxel for 1 h and allowed to grow for an additional 72 h
thereafter. ATRA-treated cells were exposed to a fixed concentra-
tion of 5 mM ATRA continuously starting 72 h prior to docetaxel
treatment. Cell growth was stopped by adding 50 ml of 50% (w/v)
trichloroacetic acid, and cellular protein was stained with sulforho-
damine B and measured by spectrophotometry (Skehan et al,
1990). Control plates were fixed to estimate the cellular protein at
time 0. The relative growth rate, r, was calculated as reported
previously (Skehan et al, 1990). Each experiment was performed
in triplicate, and IC50 values were estimated by linear interpolation
at r = 0.5. 
Median effect analysis 
Median effect analysis was used to determine the nature of the
interaction between docetaxel and ATRA (Chou and Talalay,
1984; Chou and Chou, 1986). The combination index was deter-
mined from growth rate assays at increasing levels of growth inhi-
bition (Chou and Talalay, 1984; Chou and Chou, 1986). CI values
of less than or greater than one indicate synergy and antagonism,
respectively; whereas a CI value of 1 indicated additivity of the
drugs. Drugs were combined at a ratio equal to the ratio of the IC50
values for each drug determined by growth rate assay. The combi-
nation was compared to the cytotoxicity of each drug alone in
every experiment. 
Detection of apoptotic cells 
Cells were exposed to docetaxel for 1 h at an IC20 in either the pres-
ence of or the absence of ATRA. 48 and 72 h after docetaxel
treatment, cells were collected by trypsinization and resuspended in
PBS containing 4 mg ml–1 acridine orange and 4 mg ml–1 ethidium
bromide. Subsequently, cells were assessed for apoptotic
morphology by supravital fluorescence microscopy. Cells were
scored as apoptotic according to established morphologic criteria
(McGahon et al, 1995). Cells with intact cytoplasmic membranes,
as reflected by green fluorescent condensed nuclei, were scored
as early apoptotic, and cells with red fluorescent condensed nuclei
as late apoptotic. 
Cell cycle phase distribution 
Approximately 1 to 2 ´ 106 cells were exposed to 10 nM docetaxel
for 1 h in either the presence of or the absence of ATRA. At 0, 1, 2
and 3 days after docetaxel treatment, cells were harvested by
trypsinization, washed twice with ice-cold PBS, and fixed in ice-
cold 70% ethanol at a concentration of 106 cells ml–1. Cells were
counted and 106 cells per sample were centrifuged, resuspended in
300 ml of ice-cold PBS and treated with 0.1 mg ml–1 RNase A
(Sigma Chemical Co) at 37˚C for 30 min. Propidium iodide (Mole-
cular Probes, Eugene, OR) at a final concentration of 50 mg ml–1
was then added to the cell suspensions. After a 30 min incubation
on ice, cells were analysed on a FACScan flow cytometer (Becton-
Dickinson, San Jose, CA). Multicycle AV Cell Cycle software
(Phoenix Flow Systems, San Diego, CA) was used to calculate the
fraction of cells in each phase of the cell cycle, as described previ-
ously by Dean and Jett (1974). 
Protein extraction and Western blotting 
Logarithmically growing cells were treated with docetaxel for 
1 h at an IC20 in either the presence of or the absence of ATRA. 
At 12, 24, 48 and 72 h after the beginning of docetaxel exposure,
cells were lysed in 100 ml of lysis buffer (10 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 5 mM
DTT, 1 mM sodium vanadate, 0.1 mM phenylmethylsulfonyl
fluoride, and 5 mM aminocaproic acid) for 30 min on ice. For 
the detection of PARP cleavage, DNA was sheared by passing
the cell lysates through a 25 gauge needle several times. The 
insoluble material was removed by centrifugation at 30 000 g
for 20 min at 4˚C. 50 mg of total protein was subjected to 
electrophoresis on polyacrylamide gels. Total protein was trans-
ferred to polyvinylidene difluoride membranes (Immobilon P,
Millipore, Bedford, MA) by electroblotting. The blots were stained
with the following antibodies: polyclonal anti-phospho-MAPK and
anti-phospho-p34cdc2 (New England Biolabs, Inc, Beverly, MA),
polyclonal anti-Bcl-2 and monoclonal anti-p53 (Santa Cruz
Biotechnology), and monoclonal-anti-Bcl-2 (Genosys, Woodland,
TX). The monoclonal C-2-10 anti-PARP antibody was from Dr G
Poirier (University of Laval, Canada). After washing the blots,
horseradish peroxidase-conjugated antirabbit or anti-mouse anti-
bodies diluted 1:3000 (Amersham Life Science Inc, Arlington
Heights, IL) were added, and complexes were visualized by
enhanced chemiluminescence (Amersham Life Science Inc). 
Densitometry 
Levels of protein expression were quantitated using an HP ScanJet
5100 C Scanner (Hewlett-Packard Company, Greeley, CO). 
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Effect of ATRA on docetaxel toxicity 
DU145 and LNCaP cells were exposed to increasing concentra-
tions of docetaxel for 1 h in either the presence of or the absence of
ATRA (Figure 1). Exposure to ATRA was started 72 h prior to
docetaxel and continued for 72 h thereafter. The dose of ATRA
was fixed at 5 mM. In LNCaP cells, ATRA caused a 2.5 ± 0.3-fold
increase in docetaxel toxicity as quantitated by the ratio of the IC50
values (n = 3, P = 0.04 by 2-sided t-test). In DU145 cells, ATRA
caused a 3.0 ± 0.4-fold increase in docetaxel toxicity (n = 3, 
P = 0.03 by 2-sided t-test). 
Median effect analysis of the interaction between
docetaxel and ATRA 
The nature of the interaction between docetaxel and ATRA was
analysed by the combination index-isobologram method (Chou and
Talalay, 1984; Chou and Chou, 1986). This procedure is based on
the median effect principle and on isobologram analysis and
allows the characterization of drug interactions with a single
number, the combination index. Figure 2 shows plots of the
combination index as a function of the fraction of cells affected.
In both, DU145 and LNCaP cells, the combination index was <1,
indicating strong synergy over the first 2 logs of tumour cell kill. 
Effect of ATRA on docetaxel-induced apoptosis 
Cells were exposed to docetaxel at an IC20 concentration for 1 h in
either the presence of or the absence of ATRA. The IC20 concentra-
tion was 15 nM and 10 nM in DU145 and LNCaP cells, respec-
tively. The fraction of apoptotic cells was determined at 48 and 72
h after docetaxel exposure (Figure 3). In DU145 cells, ATRA
enhanced docetaxel-induced apoptosis by 2.2 ± 0.2 fold (n = 3, P =
0.008 by 2-sided t-test) and 2.6 ± 0.2-fold (n = 3, P = 0.001), at 48
and 72 h, respectively. In LNCaP cells, ATRA had no significant
effect on docetaxel-induced apoptosis at 48 h; however, at 72 h,
ATRA enhanced docetaxel-induced apoptosis by 2.2 ± 0.2-fold 
(n = 3, P = 0.001). 
Effect of ATRA and docetaxel on Bcl-2 expression and
phosphorylation 
We have previously shown that ATRA enhances the sensitivity of
head and neck cancer cells by down-regulating Bcl-2 expression
Effect of all-trans retinoic acid on docetaxel cytotoxicity 1573
British Journal of Cancer (2001) 84(11), 1571–1576 © 2001 Cancer Research Campaign
100
10
1
100
10
1
0 10 20 30 40 0 10 20 30 50 60 40
Docetaxel concentration (nM)
DU 145 cells LNCaP cells
R
e
l
a
t
i
v
e
 
c
e
l
l
 
g
r
o
w
t
h
Figure 1 Effect of ATRA on docetaxel toxicity. LNCaP and DU145 cells
were exposed to docetaxel for 1 h in either the presence of or the absence of
ATRA. Dose–response curves were determined by sulforhodamine B growth
rate assay. Open circles, docetaxel; closed circles, docetaxel plus ATRA.
Data points represent mean ± SD of at least 3 independent experiments
performed with triplicate cultures 
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Figure 2 Combination index plots for the interaction between ATRA and
docetaxel in LNCaP and DU145 cells. The curves represent the mean of
three independent experiments performed with triplicate cultures 
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Figure 3 Effect of ATRA on docetaxel-induced apoptosis. DU145 and
LNCaP cells were exposed to docetaxel for 1 h at an IC20 in either the
presence of or the absence of ATRA. Open columns, early apoptotic cells;
shaded columns, late apoptotic cells. Columns represent mean ± SD of 3
independent experiments performed with triplicate cultures (Aebi et al, 1997). In prostate cancer cells, microtubule-damaging
agents have been shown to induce phosphorylation of Bcl-2
Haldar et al,1994,1995,1996,1997). Phosphorylation of Bcl-2 can
be demonstrated by the appearance of a slow mobility form of Bcl-
2 (Haldar et al, 1996; 1997). Bcl-2 phosphorylation has been
shown to interfere with the antiapoptotic function of Bcl-2 (Haldar
et al, 1995). Since DU145 cells do not express Bcl-2 (Haldar et al,
1996), we determined the effects of docetaxel on Bcl-2 expression
and phosphorylation only in LNCaP cells. 
LNCaP cells were exposed to 10 nM docetaxel for 1 h (IC20) in
either the presence of or the absence of ATRA (Figure 4). Docetaxel
treatment resulted in the appearance of a slow mobility form of Bcl-
2 which corresponds to the phosphorylated form of Bcl-2 (Haldar
et al, 1996, 1997). The slow mobility form of Bcl-2 was most
prominent at 24 h after exposure to docetaxel. Treatment with
ATRA alone had no major effect on Bcl-2 expression and phos-
phorylation. However, combined treatment with ATRA and
docetaxel resulted in down-regulation of Bcl-2 expression which
was most marked at 48 h. 
Effect of ATRA and docetaxel on PARP cleavage 
To further assess apoptotic cell death, we investigated the effects
of ATRA and docetaxel on PARP cleavage. PARP is a specific
substrate of the apopain/CPP32 protease (Nicholson et al, 1995).
The appearance of an 85 kD fragment indicates cleavage of PARP
by apopain/CPP32 (Kaufmann et al, 1993). In both, LNCaP and
DU145 cells, treatment with docetaxel resulted in PARP cleavage
which was most prominent at 48 h (Figures 4 and 5). Treatment
with ATRA alone resulted in the appearance of a faint 85 kD
PARP fragment. In LNCaP cells, ATRA markedly enhanced
docetaxel-induced PARP cleavage at 24 h. 
Effect of ATRA and docetaxel on p53 expression 
In LNCaP and DU145 cells, ATRA and docetaxel had no effect on
the level of expression of p53 (Figures 4 and 5). 
Effect of ATRA and docetaxel on cell cycle phase
distribution 
DU145 cells were exposed to 15 nM docetaxel for 1 h which
corresponded to an IC20 and IC40 in the absence of and in the pres-
ence of ATRA, respectively. Treatment with ATRA alone caused a
G1 arrest (Figure 6). Treatment with docetaxel alone caused a
marked and prolonged G2/M arrest which peaked at 24 and 48 h.
Compared with docetaxel treatment, combined treatment with
ATRA and docetaxel caused a G2/M arrest that was much less
prominent and more rapidly reversible. Similar results were
obtained in LNCaP cells (data not shown). 
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Figure 4 Effect of ATRA and docetaxel on expression of Bcl-2, PARP and
p53 in LNCaP cells. Cells were exposed to 10 nM docetaxel for 1 h (IC20) in
either the presence of or the absence of ATRA. Cellular proteins were
analysed by SDS PAGE and Western blotting. Bcl-2 expression and
phosphorylation. Treatment with docetaxel resulted in the appearance of a
slow mobility form of Bcl-2 which has been shown to correspond to the
phosphorylated form of Bcl-2 (Haldar et al, 1995, 1996). Combined treatment
with ATRA and docetaxel resulted in down-regulation of Bcl-2 expression.
PARP cleavage. Treatment with docetaxel resulted in cleavage of PARP.
ATRA markedly enhanced docetaxel-induced PARP cleavage at 24 h. p53
expression. ATRA and docetaxel had no effect on the expression of p53 
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Figure 5 Effect of ATRA and docetaxel on expression of PARP and p53 in
DU145 cells. Cells were exposed to 15 nM docetaxel for 1 h (IC20) in either
the presence of or the absence of ATRA. In DU145 cells, docetaxel treatment
resulted in PARP cleavage at 24 and 48 h. ATRA and docetaxel had no effect
on the expression of p53 
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Figure 6 Effect of ATRA and docetaxel on cell cycle phase distribution.
DU145 cells were exposed to 15 nM docetaxel for 1 h (IC20) in either the
presence of or the absence of ATRA. Cell cycle phase distribution was
determined by flow cytometry. Data points represent mean ± SD of 3 different
experiments Effect of ATRA on docetaxel induced G2/M arrest 
In order to better quantitate the effect of ATRA on docetaxel-
induced G2/M arrest, we calculated the area under the curve for
the fraction of cells in each phase of the cell cycle over time
(percent ´ days). The AUC for the G2/M phase was 193 ± 20
(percent of cells in G2/M phase ´ days, n = 3, mean ± SD) in
docetaxel-treated DU145 cells. Combined treatment with ATRA
and docetaxel reduced the AUC for the G2/M phase to 92 ± 15
(percent of cells in G2/M phase ´ days, n = 3, mean ± SD). This
represents a 50% reduction in G2/M arrest which was statistically
significant (n = 3, P = 0.002 by 2-sided t-test). Similarly, ATRA
reduced the AUC for the G2/M phase in docetaxel-treated LNCaP
cells by 43 ± 6% (n = 3, mean ± SD, P = 0.006 by 2-sided t-test). 
Effect of ATRA and docetaxel on p34 cdc2
phosphorylation 
cdc2 plays a critical role in the G2/M transition. The phosphoryl-
ated form of cdc2 is inactive resulting in G2/M arrest (Shapiro and
Hapre, 1999). DU145 cells were exposed to 15 nM docetaxel for 
1h  ( I C 20) in either the presence of or the absence of ATRA.
Docetaxel treatment resulted in phosphorylation of cdc2 (Figure
7). Phosphorylated cdc2 was most abundant at 48 h after docetaxel
treatment. Treatment with ATRA did not have a major effect on
cdc2 phosphorylation. However, when combined with docetaxel,
ATRA reduced docetaxel-induced cdc2 phosphorylation at 48 h,
resulting in activation of cdc2 and partial reversal of docetaxel-
induced G2/M arrest. 
Effect of ATRA and docetaxel on activation of MAPK 
Microtubule damaging agents have been shown to activate MAPK
without altering the level of MAPK expression (Ding et al, 1996;
Wang et al, 1998; Shtil et al, 1999). We therefore investigated the
effects of ATRA and docetaxel on MAPK activity. MAPK activity
was determined by immunoblotting using an antibody directed
against the phosphorylated form of MAPK. Phosphorylation of
MAPK has been shown to result in MAPK activation (Lin et al,
1995). In DU145 cells, docetaxel treatment resulted in phosphoryl-
ation of p44 and p42 MAPK which peaked at 48 h (Figure 7).
Treatment with ATRA alone had no major effect on p44/p42
MAPK phosphorylation. However, ATRA markedly reduced
docetaxel-induced MAPK phosphorylation. 
DISCUSSION 
Prostate cancer cells are intrinsically resistant to many chemother-
apeutic agents. Therefore, novel strategies aimed at reversing drug
resistance are urgently needed. We report that ATRA enhances the
in vitro toxicity of docetaxel against prostate cancer cells, and that
the nature of the interaction between ATRA and docetaxel is truly
synergistic in nature. In addition, we demonstrate that docetaxel
induces apoptotic cell death in prostate cancer cells and that ATRA
enhances docetaxel-induced apoptosis. 
Our results confirm previous reports indicating that treatment
of prostate cancer cells with docetaxel results in phosphoryla-
tion of Bcl-2 (Haldar et al, 1997). Phosphorylation of Bcl-2 at
serine residues has been shown to interfere with the anti-apop-
totic function of Bcl-2 by preventing binding of Bcl-2 to the pro-
apoptotic protein bax (Haldar et al, 1995). Treatment of LNCaP
cells with ATRA alone had no major effect on the expression or
phosphorylation of Bcl-2. However, combined treatment with
ATRA and docetaxel caused down-regulation of Bcl-2. This obser-
vation is in line with previous reports indicating that ATRA
combined with cytotoxic agents results in downregulation of Bcl-2
expression and enhanced drug sensitivity (Hu et al, 1995, 1998;
Bradbury et al, 1996; Nagy et al, 1996; Aebi et al, 1997; Pisani et
al, 1997; Andreeff et al, 1999). 
Docetaxel-induced microtubule damage caused a marked and
prolonged G2/M arrest which peaked at 24 and 48 h and which
was partially reversed by ATRA. The G2/M arrest coincided with
docetaxel-induced phosphorylation and inactivation of cdc2. In the
G2/M transition, the cyclin-dependent protein kinase complex,
cdc2 cyclin B1 complex, plays a critical role (Shapiro and Hapre,
1999). The kinase activity of cdc2 is controlled during the cell cycle
both by its association with cyclin B1 and by phosphorylation and
dephosphorylation on the inhibitory phosphorylation sites. The
phosphorylated form of cdc2 is inactive resulting in G2/M arrest. 
In DU145 cells, treatment with docetaxel resulted in phosphoryl-
ation of MAPK which also peaked at 48 h. Phosphorylation of
MAPK has been shown to be associated with activation of MAP
kinase activity (Lin et al, 1995), and activation of MAPK has been
shown to result in phosphorylation of cdc2 resulting in inactivation
of cdc2 and G2/M arrest (Bitangcol et al, 1998). Thus our findings
suggests that docetaxel-induced microtubule damage triggers a
signalling pathway that involves activation of MAPK resulting in
phosphorylation and hence inactivation of cdc2 which, in turn,
results in G2/M arrest. 
Treatment of DU145 cells with ATRA alone had no major effect
on the phosphorylation status of MAPK and cdc2. However,
ATRA inhibited docetaxel-induced phosphorylation of MAPK and
cdc2. Inhibition of docetaxel-induced phosphorylation of cdc2
resulted in activation of cdc2 and partial reversal of the docetaxel-
induced G2/M arrest. 
We conclude that ATRA synergistically enhances docetaxel
toxicity by down-regulating Bcl-2 expression and that ATRA
partially reverses the docetaxel-induced G2/M arrest by inhibiting
docetaxel-induced cdc2 phosphorylation in a pathway that is
dependent on MAPK. 
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